In compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’), Abbott India has informed that upon recommendation of the Nomination and Remuneration Committee, the Board of Directors have approved the appointment of Murari Ranganathan as Commercial Director - Women’s Health, Metabolics and International Business effective May 2, 2024. He will be part of the Senior Management team of the Company. The additional details required under the SEBI Listing Regulations read with SEBI Circular Nos. CIR/CFD/CMD/412015 dated September 9, 2015 is enclosed as Annexure A.
The above information is a part of company’s filings submitted to BSE.
